Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2

Bone Marrow Transplantation volume 40, pages 541–547 (2007)Cite this article

Abstract

A regimen of busulfan and cyclophosphamide (BuCy2) is regarded as the standard myeloablative regimen for SCT. This study evaluated the hypothesis that fludarabine can replace cyclophosphamide for myeloablative allogeneic SCT. Ninety-five patients underwent allogeneic SCT from HLA-identical donors, following BuCy2 (n=55) or busulfan+fludarabine (BF, n=40). The efficacy of fludarabine compared to cyclophosphamide was retrospectively evaluated. The BF group exhibited a shorter duration until engraftment (P=0.001), lower incidence of acute and chronic GVHD (P<0.001 and P=0.003, respectively), and non-relapse mortality (NRM) (P=0.039). Furthermore, the event-free survival and overall survival were significantly higher for the BF group compared to the BuCy2 group (P=0.004 and 0.002, respectively). After adjusting for age, the risk status of disease, GVHD prophylaxis and donor type, the BF regimen was found to be an independent favorable risk factor for event-free survival (hazard ratio (HR), 0.181; 95% confidence interval, 0.045–0.720; P=0.016) and overall survival (HR, 0.168; 0.035–0.807; P=0.026). The replacement of cyclophosphamide with fludarabine for myeloablative conditioning seems to be more effective in terms of short-term NRM, and GVHD compared to BuCy2 regimen in allogeneic transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043–2048.

    Article  CAS  PubMed  Google Scholar 

  2. Gandhi V, Plunkett W . Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41: 93–103.

    Article  CAS  PubMed  Google Scholar 

  3. Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W et al. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 1997; 57: 1487–1494.

    CAS  PubMed  Google Scholar 

  4. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  5. Bornhauser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001; 7: 2254–2262.

    CAS  PubMed  Google Scholar 

  6. Murotani Y, Kuroda J, Kimura S, Terao K, Fukiya E, Ozawa M et al. Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications. Clin Lab Haematol 2002; 24: 303–306.

    Article  CAS  PubMed  Google Scholar 

  7. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441–445.

    Article  CAS  PubMed  Google Scholar 

  8. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864.

    Article  CAS  PubMed  Google Scholar 

  9. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820–826.

    Article  PubMed  Google Scholar 

  10. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468–476.

    Article  CAS  PubMed  Google Scholar 

  11. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N et al. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 477–482.

    Article  CAS  PubMed  Google Scholar 

  12. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD . Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358–1364.

    CAS  PubMed  Google Scholar 

  13. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267–276.

    CAS  PubMed  Google Scholar 

  14. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  15. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005; 90: 939–948.

    PubMed  Google Scholar 

  16. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  PubMed  Google Scholar 

  17. DeLeve LD . Hepatic venoocclusive disease: a major complication of hematopoietic stem cell transplantation in cancer patients. Tumori 2001; 87: S27–S29.

    Article  CAS  PubMed  Google Scholar 

  18. DeLeve LD . Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830–837.

    Article  CAS  PubMed  Google Scholar 

  19. Shulman HM, Luk K, Deeg HJ, Shuman WB, Storb R . Induction of hepatic veno-occlusive disease in dogs. Am J Pathol 1987; 126: 114–125.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996; 14: 1484–1494.

    Article  CAS  PubMed  Google Scholar 

  21. Ferrara JL . Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000; 9: 299–306.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea

    Y S Chae, S K Sohn, J G Kim, Y Y Cho & J H Moon

  2. Department of Hematology/Oncology, Chonnam National University Hospital, Gwangju, Korea

    H J Shin, J S Chung & G J Cho

  3. Department of Hematology/Oncology, Pusan National University Hospital, Pusan, Korea

    D H Yang, J-J Lee, Y-K Kim & H-J Kim

Authors
  1. Y S Chae
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S K Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J G Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Y Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J H Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H J Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J S Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G J Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D H Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J-J Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Y-K Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S K Sohn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chae, Y., Sohn, S., Kim, J. et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant 40, 541–547 (2007). https://doi.org/10.1038/sj.bmt.1705770

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705770

Keywords

This article is cited by

Search

Advanced search

Quick links